Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside (NR), vitamin B3 derivative, for the treatment of Werner syndrome (WS), a rare genetic disorder. The study found that it enhances cardiovascular, skin and kidney health in patients, offering treatment potential for a disease which […]
The post Trial into rare genetic disease Werner syndrome reports promising results appeared first on Pharmafile.
